Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Drugs made to treat diabetes and weight loss could stop or even reverse a severe liver disease, according to a new study. The ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.